Mosunetuzumab (Lunsumio)
Jump to navigation
Jump to search
Mechanism of action
From the NCI Drug Dictionary: A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20-CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
Diseases for which it is used
History of changes in FDA indication
- 2022-12-22: Initial approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. (Based on GO29781)
History of changes in EMA indication
- 2022-06-03: Initial conditional authorization as monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. (Based on GO29781)
Also known as
- Code names: BTCT-4465A, RG-7828
- Generic name: mosunetuzumab-axgb
- Brand name: Lunsumio